
CONMED (CNMD) Stock Forecast & Price Target
CONMED (CNMD) Analyst Ratings
Bulls say
Conmed Corp has demonstrated notable growth in its high-potential segments, particularly with the recent success of the BioBrace, which is expected to further bolster revenue following its full release in the third quarter of 2025. The dual-digit growth observed in the Foot & Ankle category, despite supply constraints, indicates a potential easing of these issues and reflects a resilient demand for the company's products. Management's cautious revenue guidance reinforces the company’s commitment to a sustainable top-line turnaround, further supporting a positive outlook for Conmed's financial performance.
Bears say
Conmed Corp has experienced a 27% decline in its stock year-to-date, indicating significant challenges in its turnaround efforts. The company faces ongoing capital weakness, particularly in international markets, which can be attributed to difficult year-over-year comparisons rather than an overall slowdown in hospital capital budgets. This situation has led to a revision of the price target, reflecting the company's struggles amidst a backdrop of intensified competitive pressures and operational challenges.
This aggregate rating is based on analysts' research of CONMED and is not a guaranteed prediction by Public.com or investment advice.
CONMED (CNMD) Analyst Forecast & Price Prediction
Start investing in CONMED (CNMD)
Order type
Buy in
Order amount
Est. shares
0 shares